qPET - A quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 7, 2014, Pages 1301-1308

  Hasenclever, Dirk ^a   Kurch, Lars ^b   Mauz Körholz, Christine ^c   Elsner, Andreas ^d   Georgi, Thomas ^b   Wallace, Hamish ^e   Landman Parker, Judith ^f   Moryl Bujakowska, Angelina ^g   Cepelová, Michaela ^h   Karlén, Jonas ⁱ   Álvarez Fernández Teijeiro, Ana ^j   Attarbaschi, Andishe ^k   Fosså, Alexander ^l   Pears, Jane ^m   Hraskova, Andrea ⁿ   Bergsträsser, Eva ^o   Beishuizen, Auke ^p   Uyttebroeck, Anne ^q   Schomerus, Eckhard ^r   Sabri, Osama ^b   Körholz, Dieter ^c   Kluge, Regine ^b   more..

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^d HERMES MEDICAL SOLUTIONS   (Sweden)

^e ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^f ARMAND TROUSSEAU HOSPITAL   (France)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m OUR LADY S CHILDREN S HOSPITAL   (Ireland)

ⁿ University Children's Hospital   (Slovakia)

^o UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^p SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

FDG PET; Lymphoma; Response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HODGKIN DISEASE; HUMAN; LIVER; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; VISUAL ILLUSION; DIAGNOSTIC USE; IMAGE PROCESSING; METABOLISM; PROCEDURES; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADOLESCENT; BIOLOGICAL TRANSPORT; CHILD; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; POSITRON-EMISSION TOMOGRAPHY;

EID: 84903750626     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2715-9     Document Type: Article

References (40)

1. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD 15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791-9.
2. Gonzalez-Barca E, Canales M, Cortes M, et al. Predictive value of interim 18F-FDG-PET/CT for event free survival in patient with diffus large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first line treatment. Nucl Med Commun. 2013;34:946-52.
3. Dührsen U, Hüttmann A, Jöckel KH, et al. Positron emission tomography guided therapy of aggressive non-Hodgkin-lymphomas - the PETAL trial. Leuk Lymphoma. 2009;50:1757-60.
4. Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with an interim-PET positive after two ABVD courses. Br J Haematol. 2011;152:551-60.
5. Barrington SF, Mackewn JE, Schleyer P, et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol. 2011;22:739-45.
6. Körholz D, Kluge R, Wickmann L, et al. Importance of F18-fluorodesxy-D-2-glucose positron emission tomography (FDG-PET) for staging und therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol. Onkologie. 2003;26:489-93. (Pubitemid 37409896)
7. Kluge R, Körholz D. Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma. Klin Padiatr. 2011;223:315-9.
8. Kostakoglu L, Gallamini A. Interim 18F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to Paradigm Shift? J Nucl Med. 2013;54:1082-93.
9. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performer after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91:475-81.
10. Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma. 2010;51:2171-80.
11. Bhatia S, Yasui Y, Robison LL. High risk of subsequent neoplasm continues with extended follow up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386-94. (Pubitemid 46621816)
12. Prasad PK, Signorello LK, Friedman DL, et al. Long termnon-cancer mortality in pediatric and young adult cancer survivors in Finland. Pediatr Blood Cancer. 2012;58:421-7.
13. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55:1145-52.
14. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-8. (Pubitemid 350002965)
15. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50:1257-60.
16. Gallamini A, Fiore F, Sorasio R, et al. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma. 2009;50:1761-4.
17. Meignan M. Interim PET in lymphoma: a step towards standardization. Eur J Nucl Med Mol Imaging. 2010;37:1821-3.
18. Kurch L, Mauz-Körholz C, Bertling S, et al.: The EuroNet Paediatric Hodgkin Network - Modern imaging data management for real time central review in multicentre trials. Klin Pädiatr. 2013 Epub ahead of print.
19. Keyes JW. SUV: Standard Uptake or Silly Useless Value. J Nucl Med. 1995;35:164-7.
20. Paquet N, Albert A, Foidart J, et al. Within-Patient Variability of 18-F-FDG: Standardized Uptake Values in Normal Tissues. J Nucl Med. 2004;45:784-8. (Pubitemid 47618557)
21. Boellaard R, Oyen WJG, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320-33.
22. Allen-Auerbach M, Weber WA. Measuring Response with FDG-PET: Methodological Aspects. Oncologist. 2009;14:369-77.
23. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med. 2009;50 Suppl 1:122-50.
24. Efron, B.: Size, power, and false discovery rates, http://www.stat. stanford.edu/brad/papers/Size.pdf (2006).
25. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
26. Stauss J, Franzius C, Pfluger T, et al. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008;35:1581-8.
27. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imagingwith 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885-95. (Pubitemid 46768453)
28. Horning SJ, Juweid ME, Schöder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775-7.
29. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2009;37:1824-33.
30. Furth C, Amthauer H, Hautzel H, et al. Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma - results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol. 2011;22:1198-2003.
31. Itti E, Meignan M, Berriolo-Riedinger A, et al. An International confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and delta-SUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312-20.
32. Friedberg JW. PET positive, PET negative, or PET peeve. Blood. 2010;115:752-3.
33. Meignan M, Barrington S, Itti E, et al.: Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma. 2014;55:31-7.
34. Ilivitzke A, Radan L, Ben-Arush M, et al. Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low dose CT. Pediatr Radiol. 2013;43:86-92.
35. Furth C, Steffen IG, Amthauer H, et al. Early and Late Therapy Response Assessment with [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial. J Clin Oncol. 2013;27:4385-91.
36. Cerci JJ, Pracchia LF, Linardi CCG, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin Lymphoma. JNM. 2010;51:1337-43.
37. Gallamini A, Hutchings M, Rigacci L, et al. Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography is prognostically superior to International Prognosic Score in Advanced-Stage Hodgkin's Lymphoma: A Report from a joint Italian-Danish Study. J Clin Oncol. 2007;25:3746-52. (Pubitemid 47372616)
38. Cashen AF, Dehdashti F, Luo J, et al. 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. J Clin Oncol. 2011;52:386-92.
39. Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging. 2011;38:1064-71.
40. Manohar K, Mittal BR, Raja S, et al. Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2013;54:714-9.